Artesun-Plus^®, the AS/AQ FDC anti-malarial of Fosun Pharma’s subsidiary company Guilin Pharma, was listed on the official website of pre-qualified drugs of World Health Organization on Nov. 16th 2012, which made Guilin Pharma of Fosun Pharma the third supplier of such ACT. As the company’s first pre-qualified Fixed-dose ACT, Artesun-Plus^® is also the company’s sixth anti-malarial product approved by WHO.
Since the publication of WHO’s Guidelines for the Treatment of Malaria in 2006, the artemisinin based combination therapies have now been accepted by most malaria endemic countries worldwide as the standard treatment procedure for uncomplicated malaria. In 2009, the malaria world experienced the upgrading of ACTs from co-blister products to fixed-dose combination so as to help to slow down the development of artemisinin resistance of malaria parasite. To meet the market need, Guilin Pharma of Fosun Pharma started to develop its own AS/AQ FDC in 2008 and have the product WHO pre-qualified recently.
Focusing on the health industry, Fosun Pharma consistently strives for excellence with an open mind. Besides Artesun-Plus^®, the company has another two new ACTs in its anti-malaria product pipeline. So far, the company has supplied the world over 300 million treatments of oral ACTs, which have helped to save millions of lives.
As one of China’s leading pharmaceutical groups, Fosun Pharma will always dedicate itself to the world malaria campaign.